Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Non-Current Assets for 18 consecutive years, with $1.8 billion the latest figure, recorded in Q1 2026.

• Quarterly Other Non-Current Assets fell 1.1% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (down 1.1% YoY) and the FY2025 annual result came in at $1.8 billion, up 4.01% from the prior year.
• Other Non-Current Assets fell to $1.8 billion in Q1 2026 per TEVA's latest filing, from $1.8 billion in the prior quarter.
• Over the last five years, Other Non-Current Assets for TEVA reached as high as $1.8 billion in Q2 2025 and fell as low as $434.0 million in Q2 2024.
• A 5-year average of $934.1 million and a median of $470.0 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets decreased 15.44% — and 2025, when it jumped 324.42%.
• Year by year, Other Non-Current Assets stood at $441.0 million in 2022, then grew by 6.58% to $470.0 million in 2023, then soared by 276.81% to $1.8 billion in 2024, then increased by 4.01% to $1.8 billion in 2025, then retreated by 2.61% to $1.8 billion in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.8 billion, $1.8 billion, and $1.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.